Quin-G and Tekturna HCT

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

QuiNIDine may increase the blood levels and effects of aliskiren. You may need a dose adjustment or more frequent monitoring by your doctor to safely use both medications. High blood levels of aliskiren may cause an excessive fall in blood pressure and increase the risk of a condition called hyperkalemia (high blood potassium), which in severe cases can lead to kidney failure, muscle paralysis, irregular heart rhythm, and cardiac arrest. You may be more likely to develop hyperkalemia while taking aliskiren if you are elderly, dehydrated, or have kidney disease, diabetes, or advanced heart failure. Regular or long-term use of nonsteroidal anti-inflammatory drugs such as ibuprofen or naproxen (Aleve) may also increase your risk. It is important that you maintain adequate fluid intake during treatment with aliskiren. In addition, talk to your doctor to see if you should limit consumption of potassium-rich foods such as tomatoes, raisins, figs, potatoes, lima beans, bananas, plantains, papayas, pears, cantaloupes, mangoes, and potassium-containing salt substitutes. You should seek medical attention if you experience nausea, vomiting, weakness, confusion, tingling of the hands and feet, a weak pulse, or a slow or irregular heartbeat, as these may be symptoms of hyperkalemia. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

MONITOR: Coadministration with potent inhibitors of P-glycoprotein may significantly increase the plasma concentrations and pharmacologic effects of aliskiren. The proposed mechanism is inhibition of the intestinal efflux of aliskiren via P-glycoprotein. According to the product labeling, administration of a 75 mg dose of aliskiren in combination with 200 mg and 600 mg cyclosporine, a highly potent P-glycoprotein inhibitor, resulted in an approximately 2.5-fold increase in aliskiren peak plasma concentration (Cmax) and a 5-fold increase in systemic exposure (AUC). Coadministration of 300 mg aliskiren with 240 mg verapamil, a moderate P-glycoprotein inhibitor, resulted in an approximately 2-fold increase in aliskiren Cmax and AUC.

MANAGEMENT: Pharmacologic response to aliskiren should be monitored more closely whenever a P-glycoprotein inhibitor is added to or withdrawn from therapy, and the aliskiren dosage adjusted as necessary. Patients should be advised to notify their physician if they experience excessive adverse effects of aliskiren such as dizziness, lightheadedness, diarrhea, abdominal pain, and gastroesophageal reflux. The product labeling states that no dosage adjustment is necessary during coadministration with verapamil. Nevertheless, patients should be monitored for potentially increased effects of aliskiren.

Quin-G

Generic Name: quinidine

Brand name: Quin-G, Cardioquin, Quinora, Quinidex Extentabs, Quinaglute Dura-Tabs, Quin-Release

Synonyms: n.a.

What is Quin-G?

Tekturna HCT

Generic Name: aliskiren / hydrochlorothiazide

Brand name: Tekturna HCT

Synonyms: n.a.

What is Tekturna HCT?